The prevalence and clinical implication of rare germline deleterious alterations in Chinese patients with prostate cancer: A real‐world multicenter study

Xiaochen Fei(Renji Hospital), Wei Xue(Shanghai Jiao Tong University), Jiahua Pan(University of Science and Technology of China), Wanbing Zhao(Kingmed Diagnostics), Fangqin Wang(Kingmed Diagnostics), Xinxing Du(Shanghai Jiao Tong University), Liancheng Fan(Shanghai Jiao Tong University), Tongtong Liu(Heilongjiang University of Chinese Medicine), Yanqing Wang(First Affiliated Hospital of Xiamen University), Yiming Gong(Chongqing University), Yinjie Zhu(Shanghai Jiao Tong University), Yining Yang(Kingmed Diagnostics), Wei Chen(Wenzhou Medical University), Wei Chen(Sun Yat-sen University), Baijun Dong(Renji Hospital)
Clinical and Translational Medicine
October 1, 2021
Cited by 4


Related Papers